Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Marijuana-derived compound targets pain, inflammation

21.08.2002


Researchers are developing a marijuana-derived synthetic compound to relieve pain and inflammation without the mood-altering side effects associated with other marijuana based drugs.



They say the compound could improve treatment of a variety of conditions, inctluding chronic pain, arthritis and multiple sclerosis. Their findings were presented at the 224th national meeting of the American Chemical Society, the world’s largest scientific society.

The compound, called ajulemic acid, has produced encouraging results in animal studies of pain and inflammation. It is undergoing tests in a group of people with chronic pain and could be available by prescription within two to three years, the researchers say.


"We believe that [the compound] will replace aspirin and similar drugs in most applications primarily because of a lack of toxic side effects," says Sumner Burstein, Ph.D., lead investigator in the study and a professor in the department of biochemistry and molecular pharmacology at the University of Massachusetts Medical School in Worcester. "The indications so far are that it’s safe and effective," he added.

At a safety trial of the compound conducted in France last year among 15 healthy volunteers, no clinically adverse events were reported, including gastrointestinal ulcers, which have been associated with other non-steroidal anti-inflammatory compounds such as aspirin and ibuprofen. No mood-altering effects were reported, Burstein said.

Ajulemic acid is being tested in Germany among a group of 21 patients with chronic severe pain. Results are not yet available.

In animal tests, the compound was 10 to 50 times more potent as a pain-killer than delta-9-tetrahydrocannabinol (THC), the main mood-altering ingredient of marijuana. Laboratory studies indicate that the compound, a synthetic derivative of THC, is more potent than aspirin and ibuprofen, says Burstein.

In rodent models of rheumatoid arthritis, the compound prevented joint damage associated with the disease. It could be a promising alternative to current drugs used to treat arthritis, such as COX-2 inhibitors, the researcher says. These compounds have been linked to adverse side effects, including heart attacks and stroke.

Tests of multiple sclerosis (MS) in rats have shown that the drug relieves muscle stiffness (spasticity) associated with the disease, just as natural marijuana has been shown to have a similar effect. Human studies of the drug’s effect on MS are planned.

Other evidence suggests the compound could slow the spread of cancer cells and prolong survival in mice with brain tumors. The U.S. Army is evaluating it as a topical drug to relieve the blistering effects of sulfur mustard gas.

How it works is still under investigation. The compound appears to suppress chemical mediators, such as prostaglandins and cytokines, which are known to cause inflammation, the researcher says.

With an increasing number of medically beneficial compounds being found in marijuana, researchers have been searching for years for ways to utilize these compounds therapeutically without its associated "high." They have had little success, until now.

Marinol®, the only FDA-approved, marijuana-derived drug, is available by prescription as an appetite stimulant for AIDS patients and for fighting nausea associated with cancer chemotherapy. But this drug, which is also a synthetic derivative of THC, has been reported to cause a "high" in some patients.

"Some people want the high," admits Burstein. "But the medical community wants efficacy without this effect."

The original discovery of ajulemic acid was supported by the National Institute on Drug Abuse. Indevus Pharmaceuticals, based in Lexington, Mass., is developing the drug itself under the name CT-3. Burstein owns patents on ajulemic acid.


The poster on this research, MEDI 333, will be presented at 9:00 a.m., Wednesday, Aug. 21, at the Hynes Convention Center, Hall B, during a general poster session.

Sumner H. Burstein, Ph.D., is a professor in the department of biochemistry and molecular pharmacology at the University of Massachusetts Medical School in Worcester, Mass.

— Mark T. Sampson

Charmayne Marsh | EurekAlert!

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>